CliffBio
small molecule

NUROMAX

DOXACURIUM CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameNUROMAX
Active ingredientDOXACURIUM CHLORIDE
StrengthEQ 1MG BASE/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMarch 1991
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NUROMAX patent cliff — loss of exclusivity — | CliffBio